IMTX - Immatics Short-Term Debt to Capital

Symbol and logo of brand Immatics Corp (IMTX)

Immatics N.V. (IMTX) creates unique anti-tumor agents, possessing significant pricing power due to its hidden target discovery methods. The price trend, with a value of 0.01, links this potential to the implementation of AI in molecule design and synthesis automation. The business relies on partnerships with clinics, while management minimizes dependence on specific service providers.

Current Liabilities to Capital: Immatics Corp (IMTX) for 07/04/2022 - 10/30/2026

Summary analytical data breakdowns for immatics.com (IMTX)

- stock value and consensus price forecast:
Price Chart Immatics Corp|IMTX - Broker Consensus Forecast
- market capitalization statistics:
Market Capitalization Immatics NV|IMTX - Real Price to Acquire Entire Company
- book capitalization information:
Net Assets per Single Share Immatics|IMTX - Total Stockholders' Equity|Market Value to Book Value Ratio immatics.com|IMTX - Aggregate Company Assets
- issuer credit burden and liquidity indicators:
Debt to Equity Immatics N.V.|IMTX - Long-Term Liabilities to Capital|Short-Term Debt to Capital Immatics|IMTX - Company Total Indebtedness|Debt to Book Value Immatics NV|IMTX - Long-Term Debt|Company Current Liabilities Immatics|Quick Ratio immatics.com
- company profitability and valuation multiples indicators:
IMTX - Net Financial Result
Initial company analysis:Immatics Corp IMTX
Signature product of immatics.com

This ratio measures the ability of equity to cover liabilities maturing within one year, determining financial stability and liquidity risk. By analyzing the historical trend of short-term debt to equity for Immatics N.V. (IMTX), an investor can see how partnerships with pharma behemoths minimize the debt load while scaling R&D, which reduces the probability of default and enhances the asset's investment attractiveness.

Competitors of Immatics N.V. (IMTX)

Short-Term Debt to Equity ImmunityBio Corp (IBRX)|Immunocore Corp - Short-Term Debt to Capital Ratio|Short-Term Debt to Capital JANX (Janux Therapeutics)|RCUS - Short-Term Debt to Equity Ratio|ZYME - Short-Term Debt to Equity|Current Liabilities to Capital Tango Therapeutics Inc|Iovance (IOVA) - Short-Term Debt to Equity|XNCR (Xencor Inc.) - Short-Term Debt to Equity|Short-Term Debt to Equity Compass Therapeutics|Current Liabilities to Capital replimune.com REPL|Short-Term Debt to Capital LYEL|Innate Pharma SA (IPHA) - Short-Term Indebtedness to Equity|Pyxis Oncology - Short-Term Debt to Equity Ratio|Compugen Ltd (CGEN) - Current Liabilities to Capital|IOBT: Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital STRO (sutrobio.com)|INKT: Short-Term Debt to Capital|HOWL - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Immix Biopharma Inc.|Short-Term Debt to Equity Ratio alxoncology.com (ALXO)|Short-Term Debt to Equity Cue Biopharma (CUE)|Short-Term Debt to Equity Ratio pdsbiotech.com PDSB|Sonnet BioTherapeutics Holdings - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital MAIA Biotech MAIA|LIMN - Short-Term Debt to Equity|LVTX (LAVA Therapeutics N.V.) - Short-Term Debt to Capital Ratio|NextCure, Inc. (NXTC) - Short-Term Debt to Equity|Current Liabilities to Capital Leap Therapeutics (LPTX)|Short-Term Debt to Equity Ratio INTS|SNSE - Short-Term Indebtedness to Equity|Short-Term Debt to Equity Ratio TOVX (Synthetic Biologics)|Short-Term Loans to Capital Ratio GRTS|Short-Term Debt to Capital KA (Kineta, Inc.)|Ratio of Short-Term Indebtedness to Capital NEXI|Turnstone Biologics Corporation - Short-Term Debt to Capital|Current Liabilities to Capital Vaccinex Inc.|Harpoon Tx (HARP) - Short-Term Debt to Equity